Longitudinal Whole-Genome Sequence Characterization of a Persistent Severe Acute Respiratory Syndrome Coronavirus 2 Omicron BA.5 Infection in an Immunocompromised Patient Successfully Treated With Sotrovimab 1000 mg

摘要

TO the Editor— The emergence of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) Omicron variant has compromised the efficacy of the different monoclonal antibodies (MABs) available. Some of the commercialized MABS retain certain activity against different lineages of Omicron, so strategies of escalating dose may overcome resistance developed by Omicron variant. The safety of the escalated dose of so-trovimab (1000 mg) is being tested in the RECOVERY clinical trial. We present a 50-year-old woman simultaneously diagnosed with human immunodeficiency virus (HIV) infection and diffuse large B-cell lympho-ma in November 2021. At diagnosis, the patient was severely immuno-suppressed with a CD4 count of 3. The patient received immunochemo-therapy including rituximab until March 2022.